Publications

2025

Beyer D, Vaccarin C, Schmid JV, Deberle LM, Deupi X, Schibli R, et al.
Design and preclinical evaluation of novel uPAR-targeting radiopeptides modified with an albumin-binding entity
Molecular Pharmaceutics. 2025; 22(6): 3242-3254. https://doi.org/10.1021/acs.molpharmaceut.5c00135
DORA PSI
Cerboni N, Szekér B, Dressler R, Wörle M, Eichler R, Jung TA, et al.
Unraveling the formation of Tb/Pd films by coupled reduction as targets for heavy ion-beam irradiation
Journal of Alloys and Compounds. 2025; 1010: 176954 (11 pp.). https://doi.org/10.1016/j.jallcom.2024.176954
DORA PSI
Chirindel A, Nicolas GP, Westerbergh F, McDougall L, Schmid DE, Geistlich S, et al.
First-in-human administration of [¹⁶¹Tb]Tb-SibuDAB and comparative dosimetry with standard [¹⁷⁷Lu]Lu-PSMA-I&T as part of the PROGNOSTICS phase Ia study
European Journal of Nuclear Medicine and Molecular Imaging. 2025; 52: 1628-1630. https://doi.org/10.1007/s00259-024-07009-w
DORA PSI
Cieslik PA, Roth D, Nisli E, Genz J, Berton C, Grundler PV, et al.
Light-induced synthesis and radiotheranostic treatment of gastric cancer with ¹⁶¹Tb-labeled monoclonal antibodies
JACS Au. 2025. https://doi.org/10.1021/jacsau.5c00219
DORA PSI
Florit A, de Koster EJ, Sassano S, Alic L, Pisano G, van Velden FHP, et al.
Head-to-head comparison of fibroblast activation protein inhibitors (FAPI) radiopharmaceuticals and [¹⁸F]FDG in gynaecological malignancies: systematic literature review and meta-analysis
European Journal of Nuclear Medicine and Molecular Imaging. 2025. https://doi.org/10.1007/s00259-025-07277-0
DORA PSI
Mapanao AK, Busslinger SD, Mehta A, Kegler K, Favaretto C, Grundler PV, et al.
Preclinical investigation of [¹⁴⁹Tb]Tb-DOTATATE and [¹⁴⁹Tb]Tb-DOTA-LM3 for tumor-targeted alpha therapy
European Journal of Nuclear Medicine and Molecular Imaging. 2025; 52: 1383-1398. https://doi.org/10.1007/s00259-024-07035-8
DORA PSI
Mendes F, Terry SYA, Spiegelberg D, Cornelissen B, Bolcaen J, Nonnekens J
Recommendations for reporting preclinical radiobiological studies in targeted radionuclide therapy
European Journal of Nuclear Medicine and Molecular Imaging. 2025. https://doi.org/10.1007/s00259-025-07152-y
DORA PSI
Quérel E, Biswas S, Heiss MW, Gerchow L, Wang Q, Asakura R, et al.
Overcoming the probing-depth dilemma in spectroscopic analyses of batteries with muon-induced X-ray emission (MIXE)
Journal of Materials Chemistry A. 2025; 13(3): 2275 (10 pp.). https://doi.org/10.1039/d4ta05112b
DORA PSI
Rioja-Blanco E, Banz Y, Schlapbach C, Novak U, Chiorazzo T, Bertschi NL, et al.
¹⁶¹Tb Radioimmunotherapy as a treatment for CD30-positive lymphomas
Journal of Nuclear Medicine. 2025; 66(6): 909-915. https://doi.org/10.2967/jnumed.124.268805
DORA PSI
Ritt P, Fernández R, Soza-Ried C, Nicolai H, Amaral H, Krieger K, et al.
Biodistribution and dosimetry of [¹⁷⁷Lu]Lu-SibuDAB in patients with metastatic castration-resistant prostate cancer
European Journal of Nuclear Medicine and Molecular Imaging. 2025; 52: 2431-2443. https://doi.org/10.1007/s00259-025-07102-8
DORA PSI
Todorov TZ, Coelho R, Dellea S, Jacob F, Heinzelmann-Schwarz V, Grundler PV, et al.
¹⁶¹Tb-based anti-L1CAM radioimmunotherapy shows superior efficacy in eliminating ovarian cancer stem cells compared with ¹⁷⁷Lu in preclinical models of ovarian cancer
Journal of Nuclear Medicine. 2025; 66(7): 1091-1096. https://doi.org/10.2967/jnumed.124.269078
DORA PSI
Todorov TZ, Coelho R, Jacob F, Heinzelmann-Schwarz V, Schibli R, Béhé M, et al.
Phosphoproteomics reveals L1CAM-associated signaling networks in high-grade serous ovarian carcinoma: implications for radioresistance and tumorigenesis
International Journal of Molecular Sciences. 2025; 26(10): 4585 (15 pp.). https://doi.org/10.3390/ijms26104585
DORA PSI
Vaccarin C, Beyer D, Moiseeva A, Favaretto C, van der Meulen NP, Hunkeler BD, et al.
Development of lisinopril radioconjugates for nuclear imaging of the angiotensin converting enzyme
European Journal of Nuclear Medicine and Molecular Imaging. 2025. https://doi.org/10.1007/s00259-025-07386-w
DORA PSI
Wallimann RH, Mehta A, Mapanao AK, Köster U, Kneuer R, Schindler P, et al.
Preclinical comparison of (radio)lanthanides using mass spectrometry and nuclear imaging techniques: biodistribution of lanthanide-based tumor-targeting agents and lanthanides in ionic form
European Journal of Nuclear Medicine and Molecular Imaging. 2025; 52: 1370-1382. https://doi.org/10.1007/s00259-024-07018-9
DORA PSI
Wehrmüller JE, Frei JC, Hechler T, Kulke M, Pahl A, Béhé M, et al.
Site-specific modification of native IgGs with flexible drug-load
ChemBioChem. 2025; 26(8): e202400511 (6 pp.). https://doi.org/10.1002/cbic.202400511
DORA PSI
Wilson JM, Herrmann D, Grundler PV, van der Meulen NP, Sommerhalder A, Steinegger P
Quantitative gas-phase separation of carrier-free thallium radioisotopes from proton-irradiated ^natHgO
Journal of Radioanalytical and Nuclear Chemistry. 2025: 111581 (6 pp.). https://doi.org/10.1007/s10967-025-10125-y
DORA PSI

2024

Corpetti M, Müller C, Beltran H, de Bono J, Theurillat JP
Prostate-specific membrane antigen–targeted therapies for prostate cancer: towards improving therapeutic outcomes
European Urology. 2024; 85(3): 193-204. https://doi.org/10.1016/j.eururo.2023.11.018
DORA PSI
Favaretto C, Grundler PV, Talip Z, Köster U, Johnston K, Busslinger SD, et al.
Terbium-149 production: a focus on yield and quality improvement towards preclinical application
Scientific Reports. 2024; 14(1): 3284 (12 pp.). https://doi.org/10.1038/s41598-024-53610-2
DORA PSI
Fricke J, Westerbergh F, McDougall L, Favaretto C, Christ E, Nicolas GP, et al.
First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([¹⁶¹Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum
European Journal of Nuclear Medicine and Molecular Imaging. 2024; 51: 2517-2519. https://doi.org/10.1007/s00259-024-06641-w
DORA PSI
Gomes CV, Mendes BM, Paixão L, Gnesin S, Müller C, van der Meulen NP, et al.
Comparison of the dosimetry of scandium-43 and scandium-44 patient organ doses in relation to commonly used gallium-68 for imaging neuroendocrine tumours
EJNMMI Physics. 2024; 11(1): 61 (14 pp.). https://doi.org/10.1186/s40658-024-00669-5
DORA PSI
Gutmann M, Reinhardt D, Seidensticker C, Raschig M, Hahn L, Moscaroli A, et al.
Matrix metalloproteinase-responsive delivery of PEGylated fibroblast growth factor 2
ACS Biomaterials Science & Engineering. 2024; 10(1): 156-165. https://doi.org/10.1021/acsbiomaterials.3c01511
DORA PSI
Holzleitner N, Cwojdzinski T, Beck R, Urtz-Urban N, Hillhouse CC, Grundler PV, et al.
Preclinical evaluation of gastrin-releasing peptide receptor antagonists labeled with ¹⁶¹Tb and ¹⁷⁷Lu: a comparative study
Journal of Nuclear Medicine. 2024; 65(3): 481-484. https://doi.org/10.2967/jnumed.123.266233
DORA PSI
Mizuno R, Niikura M, Saito TY, Matsuzaki T, Sakurai H, Amato A, et al.
Development of wide range photon detection system for muonic X-ray spectroscopy
Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment. 2024; 1060: 169029 (14 pp.). https://doi.org/10.1016/j.nima.2023.169029
DORA PSI
Moiseeva AN, Favaretto C, Talip Z, Grundler PV, van der Meulen NP
Terbium sisters: current development status and upscaling opportunities
Frontiers in Nuclear Medicine. 2024; 4: 1472500 (14 pp.). https://doi.org/10.3389/fnume.2024.1472500
DORA PSI
Müller C, van der Meulen NP
Terbium "Sisters": more than just a "Swiss Army Knife"
In: Prasad V, ed. Beyond becquerel and biology to precision radiomolecular oncology: festschrift in honor of Richard P. Baum. Cham: Springer; 2024:225-236. https://doi.org/10.1007/978-3-031-33533-4_23
DORA PSI
Rottenburger C, Hentschel M, Fürstner M, McDougall L, Kottoros D, Kaul F, et al.
In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [¹⁷⁷Lu]Lu-PP-F11N in humans: the lumed phase 0b study
EJNMMI Research. 2024; 14(1): 37 (13 pp.). https://doi.org/10.1186/s13550-024-01101-w
DORA PSI
Sarogni P, Brindani N, Zamborlin A, Gonnelli A, Menicagli M, Mapanao AK, et al.
Tumor growth-arrest effect of tetrahydroquinazoline-derivative human topoisomerase II-alpha inhibitor in HPV-negative head and neck squamous cell carcinoma
Scientific Reports. 2024; 14(1): 9150 (10 pp.). https://doi.org/10.1038/s41598-024-59592-5
DORA PSI
Scott PJH, Penuelas I, Rey A, Aime S, Ambikalmajan PMR, Antunes IF, et al.
Highlight selection of radiochemistry and radiopharmacy developments by editorial board
EJNMMI Radiopharmacy and Chemistry. 2024; 9: 67 (20 pp.). https://doi.org/10.1186/s41181-024-00296-6
DORA PSI
Song Y, Zou J, Castellanos EA, Matsuura N, Ronald JA, Shuhendler A, et al.
Theranostics - a sure cure for cancer after 100 years?
Theranostics. 2024; 14(6): 2464-2488. https://doi.org/10.7150/thno.96675
DORA PSI
Tagliente G, Milazzo PM, Paradela C, Kopecky S, Vescovi D, Alaerts G, et al.
High-resolution cross section measurements for neutron interactions on ⁸⁹Y with incident neutron energies up to 95 keV
European Physical Journal A: Hadrons and Nuclei. 2024; 60(1): 21 (18 pp.). https://doi.org/10.1140/epja/s10050-024-01243-4
DORA PSI
Todorov TZ, Schibli R, Béhé M, Grünberg J
Targeting cancer stem cells with radioimmunotherapy: the case of the ovarian cancer stemness-associated biomarker L1CAM
International Journal of Translational Medicine. 2024; 4(3): 463-485. https://doi.org/10.3390/ijtm4030031
DORA PSI
Trachsel B, Imobersteg S, Valpreda G, Singer G, Grabherr R, Ormos M, et al.
Relaxed fibronectin: a potential novel target for imaging endometriotic lesions
EJNMMI Research. 2024; 14(1): 17 (11 pp.). https://doi.org/10.1186/s13550-024-01070-0
DORA PSI
Vaccarin C, Mapanao AK, Deberle LM, Becker AE, Borgna F, Marzaro G, et al.
Design and preclinical evaluation of a novel prostate-specific membrane antigen radioligand modified with a transthyretin binder
Cancers. 2024; 16(7): 1262 (13 pp.). https://doi.org/10.3390/cancers16071262
DORA PSI
Vaccarin C, Veit G, Hegedus T, Torres O, Chilin A, Lukacs GL, et al.
Synthesis and biological evaluation of pyrazole-pyrimidones as a new class of correctors of the cystic fibrosis transmembrane conductance regulator (CFTR)
Journal of Medicinal Chemistry. 2024; 67: 13891-13908. https://doi.org/10.1021/acs.jmedchem.4c00685
DORA PSI
Wallimann RH, Hensinger H, Müller C, Schibli R, Kneuer R, Schindler P
Liquid chromatography ICP-MS to assess the stability of ¹⁷⁵Lu- and ^natGa-based tumor-targeting agents towards the development of ¹⁷⁷Lu- and ⁶⁸Ga-labeled radiopharmaceuticals
Pharmaceutics. 2024; 16(3): 299 (13 pp.). https://doi.org/10.3390/pharmaceutics16030299
DORA PSI
de Roode KE, Joosten L, Behe M
Towards the magic radioactive bullet: improving targeted radionuclide therapy by reducing the renal retention of radioligands
Pharmaceuticals. 2024; 17(2): 256 (31 pp.). https://doi.org/10.3390/ph17020256
DORA PSI

2023

Alcayne V, Mendoza E, Cano-Ott D, Kimura A, Aberle O, Amaducci S, et al.
Results of the ²⁴⁴Cm, ²⁴⁶Cm and ²⁴⁸Cm neutron-induced capture cross sections measurements at EAR1 and EAR2 of the n_TOF facility
In: Mattoon CM, Vogt R, Escher J, Thompson I, eds. 15th international conference on nuclear data for science and technology (ND2022). Vol. 284. EPJ web conferences. Les Ulis Cedex A: EDP Sciences; 2023:01009 (6 pp.). https://doi.org/10.1051/epjconf/202328401009
DORA PSI
Beyer D, Vaccarin C, Deupi X, Mapanao AK, Cohrs S, Sozzi-Guo F, et al.
A tool for nuclear imaging of the SARS-CoV-2 entry receptor: molecular model and preclinical development of ACE2-selective radiopeptides
EJNMMI Research. 2023; 13(1): 32 (14 pp.). https://doi.org/10.1186/s13550-023-00979-2
DORA PSI
Biswas S, Megatli-Niebel I, Raselli L, Simke R, Cocolios TE, Deokar N, et al.
The non-destructive investigation of a late antique knob bow fibula (Bügelknopffibel) from Kaiseraugst/CH using Muon Induced X-ray Emission (MIXE)
Heritage Science. 2023; 11: 43 (17 pp.). https://doi.org/10.1186/s40494-023-00880-0
DORA PSI
Busslinger SD, Becker AE, Vaccarin C, Deberle LM, Renz M-L, Groehn V, et al.
Investigations using albumin binders to modify the tissue distribution profile of radiopharmaceuticals exemplified with folate radioconjugates
Cancers. 2023; 15(17): 4259 (19 pp.). https://doi.org/10.3390/cancers15174259
DORA PSI
Chen K, Mackiewicz A, Virtanen S, Grundler PV, Seifert H-P, Ritter S
Effect of zinc injection on mitigating stress corrosion cracking initiation of structural materials in light water reactor primary water
Corrosion Reviews. 2023; 41(3): 387-398. https://doi.org/10.1515/corrrev-2022-0098
DORA PSI
Chiera NM, Dressler R, Sprung P, Talip Z, Schumann D
Determination of the half-life of gadolinium-148
Applied Radiation and Isotopes. 2023; 194: 110708 (5 pp.). https://doi.org/10.1016/j.apradiso.2023.110708
DORA PSI
Dellepiane G, Casolaro P, Favaretto C, Gottstein A, Grundler PV, Mateu I, et al.
Cross-section measurement of thulium radioisotopes with an 18 MeV medical PET cyclotron for an optimized ¹⁶⁵Er production
Applied Radiation and Isotopes. 2023; 200: 110954 (11 pp.). https://doi.org/10.1016/j.apradiso.2023.110954
DORA PSI
Ermini ML, Summa M, Zamborlin A, Frusca V, Mapanao AK, Mugnaioli E, et al.
Copper nano-architecture topical cream for the accelerated recovery of burnt skin
Nanoscale Advances. 2023; 5(4): 1212-1219. https://doi.org/10.1039/d2na00786j
DORA PSI
Favaretto C, Grundler PV, Talip Z, Landolt S, Sepini L, Köster U, et al.
¹⁶¹Tb-DOTATOC production using a fully automated disposable cassette system: a first step toward the introduction of ¹⁶¹Tb into the clinic
Journal of Nuclear Medicine. 2023; 64(7): 1138-1144. https://doi.org/10.2967/jnumed.122.265268
DORA PSI
Grzmil M, Wiesmann F, Schibli R, Behe M
Targeting mTORC1 activity to improve efficacy of radioligand therapy in cancer
Cancers. 2023; 15(1): 17 (12 pp.). https://doi.org/10.3390/cancers15010017
DORA PSI
Happl B, Brandt M, Balber T, Benčurová K, Talip Z, Voegele A, et al.
Synthesis and preclinical evaluation of radiolabeled [¹⁰³Ru]BOLD-100
Pharmaceutics. 2023; 15(11): 2626 (11 pp.). https://doi.org/10.3390/pharmaceutics15112626
DORA PSI
Hofmann BA, Bolliger Schreyer S, Biswas S, Gerchow L, Wiebe D, Schumann M, et al.
An arrowhead made of meteoritic iron from the late Bronze Age settlement of Mörigen, Switzerland and its possible source
Journal of Archaeological Science. 2023; 157: 105827 (10 pp.). https://doi.org/10.1016/j.jas.2023.105827
DORA PSI
Juget F, Durán T, Nedjadi Y, Talip Z, Grundler PV, Favaretto C, et al.
Activity measurement of ⁴⁴Sc and calibration of activity measurement instruments on production sites and clinics
Molecules. 2023; 28(3): 1345 (10 pp.). https://doi.org/10.3390/molecules28031345
DORA PSI
Kiss OC, Scott PJH, Behe M, Penuelas I, Passchier J, Rey A, et al.
Highlight selection of radiochemistry and radiopharmacy developments by editorial board
EJNMMI Radiopharmacy and Chemistry. 2023; 8(1): 6 (18 pp.). https://doi.org/10.1186/s41181-023-00192-5
DORA PSI
Müller C, van der Meulen NP, Schibli R
Opportunities and potential challenges of using terbium-161 for targeted radionuclide therapy in clinics
European Journal of Nuclear Medicine and Molecular Imaging. 2023; 50: 3181-3184. https://doi.org/10.1007/s00259-023-06316-y
DORA PSI
Pekeč T, Venkatachalapathy S, Shim AR, Paysan D, Grzmil M, Schibli R, et al.
Detecting radio- and chemoresistant cells in 3D cancer co-cultures using chromatin biomarkers
Scientific Reports. 2023; 13(1): 20662 (14 pp.). https://doi.org/10.1038/s41598-023-47287-2
DORA PSI
Qin Y, Imobersteg S, Frank S, Blanc A, Chiorazzo T, Berger P, et al.
Signaling network response to α-particle–targeted therapy with the ²²⁵Ac-labeled minigastrin analog ²²⁵Ac-PP-F11N reveals the radiosensitizing potential of histone deacetylase inhibitors
Journal of Nuclear Medicine. 2023; 64(6): 873-879. https://doi.org/10.2967/jnumed.122.264597
DORA PSI
Radzina M, Saule L, Mamis E, Koester U, Cocolios TE, Pajuste E, et al.
Novel radionuclides for use in nuclear medicine in Europe: where do we stand and where do we go?
EJNMMI Radiopharmacy and Chemistry. 2023; 8(1): 27 (16 pp.). https://doi.org/10.1186/s41181-023-00211-5
DORA PSI
Renaldin E, Dellepiane G, Braccini S, Sommerhalder A, Zhang H, van der Meulen NP, et al.
Study of thulium-167 cyclotron production: a potential medically-relevant radionuclide
Frontiers in Chemistry. 2023; 11: 1288588 (14 pp.). https://doi.org/10.3389/fchem.2023.1288588
DORA PSI
Ritter S, Grundler PV, Rowthu S
A decade of research on noble metal chemical addition at PSI – lessons learned
In: International conference on water chemistry in nuclear reactor systems (NPC 2023). France: Sfen; 2023:(12 pp.).
DORA PSI
Sarogni P, Zamborlin A, Mapanao AK, Logghe T, Brancato L, van Zwol E, et al.
Hyperthermia reduces irradiation-induced tumor repopulation in an in vivo pancreatic carcinoma model
Advanced Biology. 2023; 7(10): 2200229 (9 pp.). https://doi.org/10.1002/adbi.202200229
DORA PSI
Sosnin NV, Lederer-Woods C, Krtička M, Garg R, Dietz M, Bacak M, et al.
Measurement of the ⁷⁷Se (n, γ) cross section up to 200 keV at the n_TOF facility at CERN
Physical Review C: Nuclear Physics. 2023; 107(6): 065805 (9 pp.). https://doi.org/10.1103/PhysRevC.107.065805
DORA PSI
Torres-Sánchez P, Praena J, Porras I, Sabaté-Gilarte M, Lederer-Woods C, Aberle O, et al.
Measurement of the ¹⁴N(n, p) ¹⁴C cross section at the CERN n_TOF facility from subthermal energy to 800 keV
Physical Review C: Nuclear Physics. 2023; 107(6): 064617 (15 pp.). https://doi.org/10.1103/PhysRevC.107.064617
DORA PSI
Trachsel B, Valpreda G, Lutz A, Schibli R, Mu L, Béhé M
Reducing kidney uptake of radiolabelled exendin-4 using variants of the renally cleavable linker MVK
EJNMMI Radiopharmacy and Chemistry. 2023; 8(1): 21 (11 pp.). https://doi.org/10.1186/s41181-023-00206-2
DORA PSI
Tschan VJ, Busslinger SD, Bernhardt P, Grundler PV, Zeevaart JR, Köster U, et al.
Albumin-binding and conventional PSMA ligands in combination with ¹⁶¹Tb: biodistribution, dosimetry, and preclinical therapy
Journal of Nuclear Medicine. 2023; 64(10): 1625-1631. https://doi.org/10.2967/jnumed.123.265524
DORA PSI
Wallimann RH, Schindler P, Hensinger H, Tschan VJ, Busslinger SD, Kneuer R, et al.
Inductively coupled plasma mass spectrometry - a valid method for the characterization of metal conjugates in view of the development of radiopharmaceuticals
Molecular Pharmaceutics. 2023; 20(4): 2150-2158. https://doi.org/10.1021/acs.molpharmaceut.2c01092
DORA PSI

2022

Benešová M, Guzik P, Deberle LM, Busslinger SD, Landolt T, Schibli R, et al.
Design and evaluation of novel albumin-binding folate radioconjugates: systematic approach of varying the linker entities
Molecular Pharmaceutics. 2022; 19: 963-973. https://doi.org/10.1021/acs.molpharmaceut.1c00932
DORA PSI
Borgna F, Haller S, Monné Rodriguez JM, Ginj M, Grundler PV, Zeevaart JR, et al.
Combination of terbium-161 with somatostatin receptor antagonists - a potential paradigm shift for the treatment of neuroendocrine neoplasms
European Journal of Nuclear Medicine and Molecular Imaging. 2022; 49: 1113-1126. https://doi.org/10.1007/s00259-021-05564-0
DORA PSI
Borgna F, Deberle LM, Busslinger SD, Tschan VJ, Walde LM, Becker AE, et al.
Preclinical investigations to explore the difference between the diastereomers [¹⁷⁷Lu]Lu-SibuDAB and [¹⁷⁷Lu]Lu-RibuDAB toward prostate cancer therapy
Molecular Pharmaceutics. 2022; 19(7): 2105-2114. https://doi.org/10.1021/acs.molpharmaceut.1c00994
DORA PSI
Braccini S, Carzaniga TS, Dellepiane G, Grundler PV, Scampoli P, van der Meulen NP, et al.
Optimization of ⁶⁸Ga production at an 18 MeV medical cyclotron with solid targets by means of cross-section measurement of ⁶⁶Ga, ⁶⁷Ga and ⁶⁸Ga
Applied Radiation and Isotopes. 2022; 186: 110252 (9 pp.). https://doi.org/10.1016/j.apradiso.2022.110252
DORA PSI
Busslinger SD, Tschan VJ, Richard OK, Talip Z, Schibli R, Müller C
[²²⁵Ac]Ac-SibuDAB for targeted alpha therapy of prostate cancer: preclinical evaluation and comparison with [²²⁵Ac]Ac-PSMA-617
Cancers. 2022; 14(22): 5651 (16 pp.). https://doi.org/10.3390/cancers14225651
DORA PSI
Che PP, Mapanao AK, Gregori A, Ermini ML, Zamborlin A, Capula M, et al.
Biodegradable ultrasmall-in-nano architectures loaded with cisplatin prodrug in combination with ionizing radiation induces DNA damage and apoptosis in pancreatic ductal adenocarcinoma
Cancers. 2022; 14(12): 3034 (17 pp.). https://doi.org/10.3390/cancers14123034
DORA PSI
Chiera NM, Dressler R, Sprung P, Talip Z, Schumann D
High precision half-life measurement of the extinct radio-lanthanide Dysprosium-154
Scientific Reports. 2022; 12(1): 8988 (10 pp.). https://doi.org/10.1038/s41598-022-12684-6
DORA PSI
Dellepiane G, Casolaro P, Favaretto C, Grundler PV, Mateu I, Scampoli P, et al.
Cross section measurement of terbium radioisotopes for an optimized ¹⁵⁵Tb production with an 18 MeV medical PET cyclotron
Applied Radiation and Isotopes. 2022; 184: 110175 (14 pp.). https://doi.org/10.1016/j.apradiso.2022.110175
DORA PSI
Di Liddo R, Verona M, Vaccarin C, Acquasaliente L, Schrenk S, Piccione M, et al.
Preliminary discovery of small molecule inhibitors of Epidermal Growth Factor Receptor (EGFR) that bind to the extracellular domain
Cancers. 2022; 14(15): 3647 (22 pp.). https://doi.org/10.3390/cancers14153647
DORA PSI
Durán MT, Juget F, Nedjadi Y, Bailat C, Grundler PV, Talip Z, et al.
Half-life measurement of ⁴⁴Sc and ^44mSc
Applied Radiation and Isotopes. 2022; 190: 110507 (10 pp.). https://doi.org/10.1016/j.apradiso.2022.110507
DORA PSI
Eichler R, Kiselev D, Koschik A, Knecht A, van der Meulen N, Scheibl R, et al.
IMPACT conceptual design report
Villigen PSI: Paul Scherrer Institut; 2022. PSI Bericht: 22-01.
DORA PSI
Franceschinis E, Roverso M, Gabbia D, De Martin S, Brusegan M, Vaccarin C, et al.
Self-emulsifying formulations to increase the oral bioavailability of 4,6,4′-trimethylangelicin as a possible treatment for cystic fibrosis
Pharmaceutics. 2022; 14(9): 1806 (17 pp.). https://doi.org/10.3390/pharmaceutics14091806
DORA PSI
Gillings N, Hjelstuen O, Behe M, Decristoforo C, Elsinga PH, Ferrari V, et al.
EANM guideline on quality risk management for radiopharmaceuticals
European Journal of Nuclear Medicine and Molecular Imaging. 2022; 49: 3353-3364. https://doi.org/10.1007/s00259-022-05738-4
DORA PSI
Grzmil M, Boersema P, Sharma A, Blanc A, Imobersteg S, Pruschy M, et al.
Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT)
Journal of Hematology & Oncology. 2022; 15(1): 123 (5 pp.). https://doi.org/10.1186/s13045-022-01343-y
DORA PSI
Hemmingsson J, Svensson J, van der Meulen NP, Müller C, Bernhardt P
Active bone marrow S-values for the low-energy electron emitter terbium-161 compared to S-values for lutetium-177 and yttrium-90
EJNMMI Physics. 2022; 9(1): 65 (13 pp.). https://doi.org/10.1186/s40658-022-00495-7
DORA PSI
Juget F, Talip Z, Nedjadi Y, Durán MT, Grundler PV, Zeevaart JR, et al.
Precise activity measurements of medical radionuclides using an ionization chamber: a case study with Terbium-161
EJNMMI Physics. 2022; 9(1): 19 (18 pp.). https://doi.org/10.1186/s40658-022-00448-0
DORA PSI
Miller IS, Khan S, Shiels LP, Das S, O' Farrell AC, Connor K, et al.
Implementing subtype-specific pre-clinical models of breast cancer to study pre-treatment aspirin effects
Cancer Medicine. 2022; 11(20): 3820-3836. https://doi.org/10.1002/cam4.4756
DORA PSI
Rigamonti N, Veitonmäki N, Domke C, Barsin S, Jetzer S, Abdelmotaleb O, et al.
A multispecific anti-CD40 DARPin construct induces tumor-selective CD40 activation and tumor regression
Cancer Immunology Research. 2022; 10(5): 626-640. https://doi.org/10.1158/2326-6066.CIR-21-0553
DORA PSI
Schmitt J, Schwenck J, Maurer A, Przybille M, Sonanini D, Reischl G, et al.
Translational immunoPET imaging using a radiolabeled GD2-specific antibody in neuroblastoma
Theranostics. 2022; 12(13): 5615-5630. https://doi.org/10.7150/thno.56736
DORA PSI
Schwenck J, Maurer A, Beziere N, Fiz F, Boschetti F, Geistlich S, et al.
Antibody-guided molecular imaging of Aspergillus lung infections in leukemia patients
Journal of Nuclear Medicine. 2022; 63(9): 1450-1451. https://doi.org/10.2967/jnumed.121.263251
DORA PSI
Tosato M, Verona M, Favaretto C, Pometti M, Zanoni G, Scopelliti F, et al.
Chelation of theranostic copper radioisotopes with S-rich macrocycles: from radiolabelling of copper-64 to in vivo investigation
Molecules. 2022; 27(13): 4158 (19 pp.). https://doi.org/10.3390/molecules27134158
DORA PSI
Trebosc V, Lucchini V, Narwal M, Wicki B, Gartenmann S, Schellhorn B, et al.
Targeting virulence regulation to disarm Acinetobacter baumannii pathogenesis
Virulence. 2022; 13(1): 1868-1883. https://doi.org/10.1080/21505594.2022.2135273
DORA PSI
Tschan VJ, Borgna F, Schibli R, Müller C
Impact of the mouse model and molar amount of injected ligand on the tissue distribution profile of PSMA radioligands
European Journal of Nuclear Medicine and Molecular Imaging. 2022; 49: 470-480. https://doi.org/10.1007/s00259-021-05446-5
DORA PSI
Tschan VJ, Borgna F, Busslinger SD, Stirn M, Monné Rodriguez JM, Bernhardt P, et al.
Preclinical investigations using [¹⁷⁷Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer
European Journal of Nuclear Medicine and Molecular Imaging. 2022; 49: 3639-3650. https://doi.org/10.1007/s00259-022-05837-2
DORA PSI
Tupini C, Chilin A, Rossi A, De Fino I, Bragonzi A, D’Aversa E, et al.
New TMA (4,6,4′-trimethyl angelicin) analogues as anti-inflammatory agents in the treatment of cystic fibrosis lung disease
International Journal of Molecular Sciences. 2022; 23(22): 14483 (20 pp.). https://doi.org/10.3390/ijms232214483
DORA PSI
Vaccarin C, Gabbia D, Franceschinis E, De Martin S, Roverso M, Bogialli S, et al.
Improved trimethylangelicin analogs for cystic fibrosis: design, synthesis and preliminary screening
International Journal of Molecular Sciences. 2022; 23(19): 11528 (14 pp.). https://doi.org/10.3390/ijms231911528
DORA PSI
Valpreda G, Trachsel B, Vogel V, Schibli R, Mu L, Behe M
Dual MVK cleavable linkers effectively reduce renal retention of ¹¹¹In-fibronectin-binding peptides
Bioorganic and Medicinal Chemistry. 2022; 73: 117040 (11 pp.). https://doi.org/10.1016/j.bmc.2022.117040
DORA PSI
Zippel C, Ermert J, Patt M, Gildehaus FJ, Ross TL, Reischl G, et al.
Cyclotrons operated for nuclear medicine and radiopharmacy in the German Speaking D-A-CH countries: an update on current status and trends
Frontiers in Nuclear Medicine. 2022; 2: 850414 (10 pp.). https://doi.org/10.3389/fnume.2022.850414
DORA PSI

2021

Aime S, Al-Qahtani M, Behe M, Bormans G, Carlucci G, DaSilva JN, et al.
Highlight selection of radiochemistry and radiopharmacy developments by editorial board
EJNMMI Radiopharmacy and Chemistry. 2021; 6(1): 13 (19 pp.). https://doi.org/10.1186/s41181-021-00128-x
DORA PSI
Al-Qahtani M, Behe M, Bormans G, Carlucci G, Dasilva J, Decristoforo C, et al.
Highlight selection of radiochemistry and radiopharmacy developments by editorial board (January-June 2020)
EJNMMI Radiopharmacy and Chemistry. 2021; 6(1): 5 (13 pp.). https://doi.org/10.1186/s41181-020-00118-5
DORA PSI
Baum RP, Singh A, Kulkarni HR, Bernhardt P, Rydén T, Schuchardt C, et al.
First-in-human application of terbium-161: a feasibility study using ¹⁶¹Tb-DOTATOC
Journal of Nuclear Medicine. 2021; 62(10): 1391-1397. https://doi.org/10.2967/jnumed.120.258376
DORA PSI
Bernhardt P, Svensson J, Hemmingsson J, van der Meulen NP, Zeevaart JR, Konijnenberg MW, et al.
Dosimetric analysis of the short-ranged particle emitter ¹⁶¹Tb for radionuclide therapy of metastatic prostate cancer
Cancers. 2021; 13(9): 2011 (13 pp.). https://doi.org/10.3390/cancers13092011
DORA PSI
Borgna F, Barritt P, Grundler PV, Talip Z, Cohrs S, Zeevaart JR, et al.
Simultaneous visualization of ¹⁶¹Tb-and ¹⁷⁷Lu-labeled somatostatin analogues using dual-isotope SPECT imaging
Pharmaceutics. 2021; 13(4): 536 (13 pp.). https://doi.org/10.3390/pharmaceutics13040536
DORA PSI
Deberle LM, Benešová M, Becker AE, Ratz M, Guzik P, Schibli R, et al.
Novel synthetic strategies enable the efficient development of folate conjugates for cancer radiotheranostics
Bioconjugate Chemistry. 2021; 32(8): 1617-1628. https://doi.org/10.1021/acs.bioconjchem.1c00198
DORA PSI
Duchemin C, Ramos JP, Stora T, Ahmed E, Aubert E, Audouin N, et al.
CERN-MEDICIS: a review since commissioning in 2017
Frontiers in Medicine. 2021; 8: 693682 (11 pp.). https://doi.org/10.3389/fmed.2021.693682
DORA PSI
Durán MT, Juget F, Nedjadi Y, Bochud F, Talip Z, van der Meulen NP, et al.
Ytterbium-175 half-life determination
Applied Radiation and Isotopes. 2021; 176: 109893 (8 pp.). https://doi.org/10.1016/j.apradiso.2021.109893
DORA PSI
Favaretto C, Talip Z, Borgna F, Grundler PV, Dellepiane G, Sommerhalder A, et al.
Cyclotron production and radiochemical purification of terbium-155 for SPECT imaging
EJNMMI Radiopharmacy and Chemistry. 2021; 6: 37 (17 pp.). https://doi.org/10.1186/s41181-021-00153-w
DORA PSI
Früh SM, Matti U, Spycher PR, Rubini M, Lickert S, Schlichthaerle T, et al.
Site-specifically-labeled antibodies for super-resolution microscopy reveal in situ linkage errors
ACS Nano. 2021; 15(7): 12161-12170. https://doi.org/10.1021/acsnano.1c03677
DORA PSI
Gillings N, Hjelstuen O, Ballinger J, Behe M, Decristoforo C, Elsinga P, et al.
Guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals
EJNMMI Radiopharmacy and Chemistry. 2021; 6(1): 8 (22 pp.). https://doi.org/10.1186/s41181-021-00123-2
DORA PSI
Grob NM, Schibli R, Béhé M, Valverde IE, Mindt TL
1,5-Disubstituted 1,2,3-triazoles as amide bond isosteres yield novel tumor-targeting minigastrin analogs
ACS Medicinal Chemistry Letters. 2021; 12(4): 585-592. https://doi.org/10.1021/acsmedchemlett.0c00636
DORA PSI
Grob NM, Schibli R, Béhé M, Mindt TL
Improved tumor-targeting with peptidomimetic analogs of minigastrin¹⁷⁷Lu-PP-F11N
Cancers. 2021; 13(11): 2629 (12 pp.). https://doi.org/10.3390/cancers13112629
DORA PSI
Grzmil M, Imobersteg S, Blanc A, Frank S, Schibli R, Béhé MP
Therapeutic response of CCKBR-positive tumors to combinatory treatment with everolimus and the radiolabeled minigastrin analogue [¹⁷⁷Lu]Lu-PP-F11N
Pharmaceutics. 2021; 13(12): 2156 (8 pp.). https://doi.org/10.3390/pharmaceutics13122156
DORA PSI
Guzik P, Fang H-Y, Deberle LM, Benešová M, Cohrs S, Boss SD, et al.
Identification of a PET radiotracer for imaging of the folate receptor-α: a potential tool to select patients for targeted tumor therapy
Journal of Nuclear Medicine. 2021; 62(10): 1475-1481. https://doi.org/10.2967/jnumed.120.255760
DORA PSI
Guzik P, Benešová M, Ratz M, Monné Rodríguez JM, Deberle LM, Schibli R, et al.
Preclinical evaluation of 5-methyltetrahydrofolate-based radioconjugates - new perspectives for folate receptor-targeted radionuclide therapy
European Journal of Nuclear Medicine and Molecular Imaging. 2021; 48: 972-983. https://doi.org/10.1007/s00259-020-04980-y
DORA PSI
Guzik P, Siwowska K, Fang H-Y, Cohrs S, Bernhardt P, Schibli R, et al.
Promising potential of [¹⁷⁷Lu]Lu-DOTA-folate to enhance tumor response to immunotherapy - a preclinical study using a syngeneic breast cancer model
European Journal of Nuclear Medicine and Molecular Imaging. 2021; 48: 984-994. https://doi.org/10.1007/s00259-020-05054-9
DORA PSI
Haixia X, Oliveira da Silva de Barros A, do Vale Chaves e Mello F, Sozzi-Guo F, Müller C, Gemini-Piperni S, et al.
Graphene: insights on biological, radiochemical and ecotoxicological aspects
Journal of Biomedical Nanotechnology. 2021; 17(1): 131-148. https://doi.org/10.1166/jbn.2021.3006
DORA PSI
Heinke R, Chevallay E, Chrysalidis K, Cocolios TE, Duchemin C, Fedosseev VN, et al.
Efficient production of high specific activity thulium-167 at Paul Scherrer Institute and CERN-MEDICIS
Frontiers in Medicine. 2021; 8: 712374 (17 pp.). https://doi.org/10.3389/fmed.2021.712374
DORA PSI
Juget F, Talip Z, Buchillier T, Durán MT, Nedjadi Y, Desorgher L, et al.
Determination of the gamma and X-ray emission intensities of terbium-161
Applied Radiation and Isotopes. 2021; 174: 109770 (6 pp.). https://doi.org/10.1016/j.apradiso.2021.109770
DORA PSI
Kramer V, Fernández R, Lehnert W, Jiménez-Franco LD, Soza-Ried C, Eppard E, et al.
Biodistribution and dosimetry of a single dose of albumin-binding ligand [¹⁷⁷Lu]Lu-PSMA-ALB-56 in patients with mCRPC
European Journal of Nuclear Medicine and Molecular Imaging. 2021; 48: 893-903. https://doi.org/10.1007/s00259-020-05022-3
DORA PSI
Lima TVM, Gnesin S, Strobel K, del Sol Pérez M, Roos JE, Müller C, et al.
Fifty shades of scandium: comparative study of PET capabilities using Sc-43 and Sc-44 with respect to conventional clinical radionuclides
Diagnostics. 2021; 11(10): 1826 (11 pp.). https://doi.org/10.3390/diagnostics11101826
DORA PSI
Müller C, Schibli R, Bernhardt P, Köster U, van der Meulen NP
Terbium radionuclides for theranostics
In: Caplan MJ, ed. Reference module in biomedical sciences. sine loco: Elsevier; 2021:(12 pp.). https://doi.org/10.1016/B978-0-12-822960-6.00076-4
DORA PSI
Romantini N, Alam S, Dobitz S, Spillmann M, De Foresta M, Schibli R, et al.
Exploring the signaling space of a GPCR using bivalent ligands with a rigid oligoproline backbone
Proceedings of the National Academy of Sciences of the United States of America PNAS. 2021; 118(48): e2108776118 (8 pp.). https://doi.org/10.1073/pnas.2108776118
DORA PSI
Rowthu S, Grundler PV, Müller E, Ritter S
Pt catalytic effects on the corrosion and hydrogen chemisorption properties of Zircaloy-2
Journal of Nuclear Materials. 2021; 544: 152716 (15 pp.). https://doi.org/10.1016/j.jnucmat.2020.152716
DORA PSI
Taddio MF, Castro Jaramillo CA, Runge P, Blanc A, Keller C, Talip Z, et al.
In vivo imaging of local inflammation: monitoring LPS-induced CD80/CD86 upregulation by PET
Molecular Imaging and Biology. 2021; 23: 196-207. https://doi.org/10.1007/s11307-020-01543-3
DORA PSI
Talip Z, Juget F, Ulrich J, Nedjadi Y, Buchillier T, Durán MT, et al.
Determination of the gamma and X-ray emission intensities of erbium-169
Applied Radiation and Isotopes. 2021; 176: 109823 (9 pp.). https://doi.org/10.1016/j.apradiso.2021.109823
DORA PSI
Talip Z, Borgna F, Müller C, Ulrich J, Duchemin C, Ramos JP, et al.
Production of mass-separated erbium-169 towards the first preclinical in vitro investigations
Frontiers in Medicine. 2021; 8: 643175 (11 pp.). https://doi.org/10.3389/fmed.2021.643175
DORA PSI
Talip Z, Dressler R, Schacherl B, David J-C, Vockenhuber C, Schumann D
Radiochemical determination of long-lived radionuclides in proton-irradiated heavy metal targets: part II tungsten
Analytical Chemistry. 2021; 93(31): 10798-10806. https://doi.org/10.1021/acs.analchem.1c00640
DORA PSI
Wang H, Lallemang M, Hermann B, Wallin C, Loch R, Blanc A, et al.
ATP impedes the inhibitory effect of Hsp90 on Aβ₄₀ fibrillation
Journal of Molecular Biology. 2021; 433(2): 166717 (16 pp.). https://doi.org/10.1016/j.jmb.2020.11.016
DORA PSI
van der Meulen NP, Talip Z
Non-conventional radionuclides: the pursuit for perfection
In: Caplan MJ, ed. Reference module in biomedical sciences. sine loco: Elsevier; 2021:(10 pp.). https://doi.org/10.1016/B978-0-12-822960-6.00052-1
DORA PSI

2020

Alcayne V, Mendoza E, Cano-Ott D, Kimura A, Aberle O, Amaducci S, et al.
Measurement of the ²⁴⁴Cm capture cross sections at both CERN n_TOF experimental areas
In: Ge Z, Shu N, Chen Y, Wang W, Zhang H, eds. ND 2019: international conference on nuclear data for science and technology. Vol. 239. EPJ web of conferences. Sine loco: EDP Sciences; 2020:01034 (5 pp.). https://doi.org/10.1051/epjconf/202023901034
DORA PSI
Bierig T, Collu G, Blanc A, Poghosyan E, Benoit RM
Design, expression, purification, and characterization of a YFP-tagged 2019-n CoV spike receptor-binding domain construct
Frontiers in Bioengineering and Biotechnology. 2020; 8: 618615 (10 pp.). https://doi.org/10.3389/fbioe.2020.618615
DORA PSI
Borgna F, Deberle LM, Cohrs S, Schibli R, Müller C
Combined application of albumin-binding [¹⁷⁷Lu]Lu-PSMA-ALB-56 and fast-cleared PSMA inhibitors: optimization of the pharmacokinetics
Molecular Pharmaceutics. 2020; 17(6): 2044-2053. https://doi.org/10.1021/acs.molpharmaceut.0c00199
DORA PSI
Chiera NM, Talip Z, Fankhauser A, Schumann D
Separation and recovery of exotic radiolanthanides from irradiated tantalum targets for half-life measurements
PLoS One. 2020; 15(7): e0235711 (19 pp.). https://doi.org/10.1371/journal.pone.0235711
DORA PSI
Deberle LM, Tschan VJ, Borgna F, Sozzi-Guo F, Bernhardt P, Schibli R, et al.
Albumin-binding PSMA radioligands: impact of minimal structural changes on the tissue distribution profile
Molecules. 2020; 25(11): 2542 (16 pp.). https://doi.org/10.3390/molecules25112542
DORA PSI
Deberle LM, Benešová M, Umbricht CA, Borgna F, Büchler M, Zhernosekov K, et al.
Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity
Theranostics. 2020; 10(4): 1678-1693. https://doi.org/10.7150/thno.40482
DORA PSI
Dobitz S, Wilhelm P, Romantini N, De Foresta M, Walther C, Ritler A, et al.
Distance-dependent cellular uptake of oligoproline-based homobivalent ligands targeting GPCRs - an experimental and computational analysis
Bioconjugate Chemistry. 2020; 31(10): 2431-2438. https://doi.org/10.1021/acs.bioconjchem.0c00484
DORA PSI
Dodich A, Mendes A, Assal F, Chicherio C, Rakotomiaramanana B, Andryszak P, et al.
The A/T/N model applied through imaging biomarkers in a memory clinic
European Journal of Nuclear Medicine and Molecular Imaging. 2020; 47(2): 247-255. https://doi.org/10.1007/s00259-019-04536-9
DORA PSI
Durán MT, Juget F, Nedjadi Y, Bochud F, Grundler PV, Gracheva N, et al.
Determination of ¹⁶¹Tb half-life by three measurement methods
Applied Radiation and Isotopes. 2020; 159: 109085 (9 pp.). https://doi.org/10.1016/j.apradiso.2020.109085
DORA PSI
Fonta CM, Arnoldini S, Jaramillo D, Moscaroli A, Oxenius A, Behe M, et al.
Fibronectin fibers are highly tensed in healthy organs in contrast to tumors and virus-infected lymph nodes
Matrix Biology Plus. 2020; 8: 100046 (15 pp.). https://doi.org/10.1016/j.mbplus.2020.100046
DORA PSI
Gillings N, Todde S, Behe M, Decristoforo C, Elsinga P, Ferrari V, et al.
EANM guideline on the validation of analytical methods for radiopharmaceuticals
EJNMMI Radiopharmacy and Chemistry. 2020; 5(1): 7 (29 pp.). https://doi.org/10.1186/s41181-019-0086-z
DORA PSI
Gnesin S, Müller J, Burger IA, Meisel A, Siano M, Früh M, et al.
Radiation dosimetry of ¹⁸F-AzaFol: a first in-human use of a folate receptor PET tracer
EJNMMI Research. 2020; 10(1): 32 (12 pp.). https://doi.org/10.1186/s13550-020-00624-2
DORA PSI
Gracheva N, Carzaniga TS, Schibli R, Braccini S, van der Meulen NP
¹⁶⁵Er: a new candidate for Auger electron therapy and its possible cyclotron production from natural holmium targets
Applied Radiation and Isotopes. 2020; 159: 109079 (8 pp.). https://doi.org/10.1016/j.apradiso.2020.109079
DORA PSI
Grob NM, Schmid S, Schibli R, Behe M, Mindt TL
Design of radiolabeled analogs of minigastrin by multiple amide-to-triazole substitutions
Journal of Medicinal Chemistry. 2020; 63(9): 4496-4505. https://doi.org/10.1021/acs.jmedchem.9b01937
DORA PSI
Grob NM, Häussinger D, Deupi X, Schibli R, Behe M, Mindt TL
Triazolo-peptidomimetics: novel radiolabeled minigastrin analogs for improved tumor targeting
Journal of Medicinal Chemistry. 2020; 63(9): 4484-4495. https://doi.org/10.1021/acs.jmedchem.9b01936
DORA PSI
Grundler PV, Eichler R, Talip Z, Schubiger PA, Schibli R, van der Meulen NP
The metamorphosis of radionuclide production and development at Paul Scherrer Institute
Chimia. 2020; 74(12): 968-975. https://doi.org/10.2533/CHIMIA.2020.968
DORA PSI
Grzmil M, Qin Y, Schleuniger C, Frank S, Imobersteg S, Blanc A, et al.
Pharmacological inhibition of mTORC1 increases CCKBR-specific tumor uptake of radiolabeled minigastrin analogue [¹⁷⁷Lu]Lu-PP-F11N
Theranostics. 2020; 10(24): 10861-10873. https://doi.org/10.7150/thno.45440
DORA PSI
Lima TVM, Gnesin S, Nitzsche E, Ortega PG, Müller C, van der Meulen NP
First phantom-based quantitative assessment of scandium-44 using a commercial PET device
Frontiers in Physics. 2020; 8: 241 (10 pp.). https://doi.org/10.3389/fphy.2020.00241
DORA PSI
Lühmann T, Gutmann M, Moscaroli A, Raschig M, Béhé M, Meinel L
Biodistribution of site-specific PEGylated fibroblast growth factor-2
ACS Biomaterials Science & Engineering. 2020; 6(1): 425-432. https://doi.org/10.1021/acsbiomaterials.9b01248
DORA PSI
Marin I, Rydèn T, Van Essen M, Svensson J, Gracheva N, Köster U, et al.
Establishment of a clinical SPECT/CT protocol for imaging of ¹⁶¹Tb
EJNMMI Physics. 2020; 7(1): 45 (16 pp.). https://doi.org/10.1186/s40658-020-00314-x
DORA PSI
Mazzone A, Cristallo S, Aberle O, Alaerts G, Alcayne V, Amaducci S, et al.
Measurement of the ¹⁵⁴Gd(n,γ) cross section and its astrophysical implications
Physics Letters, Section B: Nuclear, Elementary Particle and High-Energy Physics. 2020; 804: 135405 (6 pp.). https://doi.org/10.1016/j.physletb.2020.135405
DORA PSI
Mendoza E, Alcayne V, Cano-Ott D, Kimura A, Skarbeli AV, Aberle O, et al.
Study of photon strength functions of ²⁴¹Pu and ²⁴⁵Cm from neutron capture measurements
In: Ge Z, Shu N, Chen Y, Wang W, Zhang H, eds. ND 2019: international conference on nuclear data for science and technology. Vol. 239. EPJ web of conferences. Les Ulis Cedex A: EDP Sciences; 2020:05006 (6 pp.). https://doi.org/10.1051/epjconf/202023901015
DORA PSI
Müller C, Schibli R, Maurer B
Can nuclear imaging of activated macrophages with folic acid-based radiotracers serve as a prognostic means to identify COVID-19 patients at risk?
Pharmaceuticals. 2020; 13(9): 238 (8 pp.). https://doi.org/10.3390/ph13090238
DORA PSI
Müller C, Béhé M, Geistlich S, van der Meulen NP, Schibli R
Targeted radiotherapeutics from 'bench-to-bedside'
Chimia. 2020; 74(12): 939-945. https://doi.org/10.2533/CHIMIA.2020.939
DORA PSI
Nedjadi Y, Juget F, Desorgher L, Durán MT, Bochud F, Müller C, et al.
Activity standardisation of ¹⁶¹Tb
Applied Radiation and Isotopes. 2020; 166: 109411 (13 pp.). https://doi.org/10.1016/j.apradiso.2020.109411
DORA PSI
Nizou G, Favaretto C, Borgna F, Grundler PV, Saffon-Merceron N, Platas-Iglesias C, et al.
Expanding the scope of pyclen-picolinate lanthanide chelates to potential theranostic applications
Inorganic Chemistry. 2020; 59(16): 11736-11748. https://doi.org/10.1021/acs.inorgchem.0c01664
DORA PSI
Oprea A, Gunsing F, Schillebeeckx P, Aberle O, Bacak M, Berthoumieux E, et al.
Neutron capture cross section measurements of ²⁴¹Am at the n_TOF facility
In: Ge Z, Shu N, Chen Y, Wang W, Zhang H, eds. ND 2019: international conference on nuclear data for science and technology. Vol. 239. EPJ web of conferences. Les Ulis Cedex A: EDP Sciences; 2020:01009 (5 pp.). https://doi.org/10.1051/epjconf/202023901009
DORA PSI
Pamula F, Mühle J, Blanc A, Nehmé R, Edwards PC, Tate CG, et al.
Strategic screening and characterization of the visual GPCR-mini-G protein signaling complex for successful crystallization
Journal of Visualized Experiments. 2020; 2020(157): e60747 (10 pp.). https://doi.org/10.3791/60747
DORA PSI
Pietzsch H-J, Mamat C, Müller C, Schibli R
Single photon emission computed tomography tracer
In: Schober O, Kiessling F, Debus J, eds. Molecular imaging in oncology. Recent results in cancer research. Cham: Springer Nature; 2020:227-282. https://doi.org/10.1007/978-3-030-42618-7_7
DORA PSI
Qin Y, Imobersteg S, Blanc A, Frank S, Schibli R, Béhé MP, et al.
Evaluation of actinium-225 labeled minigastrin analogue [²²⁵Ac]Ac-DOTA-PP-F11N for targeted alpha particle therapy
Pharmaceutics. 2020; 12(11): 1088 (12 pp.). https://doi.org/10.3390/pharmaceutics12111088
DORA PSI
Rottenburger C, Nicolas GP, McDougall L, Kaul F, Cachovan M, Vija AH, et al.
Cholecystokinin-2 receptor agonist ¹⁷⁷Lu-PP-F11N for radionuclide therapy of medullary thyroid carcinoma - results of the lumed phase 0a study
Journal of Nuclear Medicine. 2020; 61(4): 520-526. https://doi.org/10.2967/jnumed.119.233031
DORA PSI
Spillmann M, Thurner L, Romantini N, Zimmermann M, Meger B, Behe M, et al.
New insights into arrestin recruitment to GPCRs
International Journal of Molecular Sciences. 2020; 21(14): 4949 (14 pp.). https://doi.org/10.3390/ijms21144949
DORA PSI
Talip Z, Favaretto C, Geistlich S, van der Meulen NP
A step-by-step guide for the novel radiometal production for medical applications: case studies with ⁶⁸Ga, ⁴⁴Sc, ¹⁷⁷Lu and ¹⁶¹Tb
Molecules. 2020; 25(4): 966 (29 pp.). https://doi.org/10.3390/molecules25040966
DORA PSI
Terraneo N, Jacob F, Peitzsch C, Dubrovska A, Krudewig C, Huang Y-L, et al.
L1 cell adhesion molecule confers radioresistance to ovarian cancer and defines a new cancer stem cell population
Cancers. 2020; 12(1): 217 (17 pp.). https://doi.org/10.3390/cancers12010217
DORA PSI
Terraneo N, Jacob F, Dubrovska A, Grünberg J
Novel therapeutic strategies for ovarian cancer stem cells
Frontiers in Oncology. 2020; 10: 319 (17 pp.). https://doi.org/10.3389/fonc.2020.00319
DORA PSI
Zhang H, Eichler R, Grillenberger J, Hirzel W, Joray S, Kiselev DC, et al.
BDSIM simulation of the complete radionuclide production beam line from beam splitter to target station at the PSI cyclotron facility
In: Conradie L, Garrett De Villiers J, Schaa VRW, eds. CYC2019. 22nd international conference on cyclotrons and their applications. Vol. 22. International conference on cyclotrons and their applications. Geneva: JACoW Publishing; 2020:275-278. https://doi.org/10.18429/JACoW-Cyclotrons2019-WEB04
DORA PSI
van der Meulen NP, Hasler R, Talip Z, Grundler PV, Favaretto C, Umbricht CA, et al.
Developments toward the implementation of ⁴⁴Sc production at a medical cyclotron
Molecules. 2020; 25(20): 4706 (16 pp.). https://doi.org/10.3390/molecules25204706
DORA PSI
van der Meulen NP, Eichler R, Grundler PV, Hasler R, Hirzel W, Joray S, et al.
The use of PSI's IP2 beam line towards exotic radionuclide development and its application towards proof-of-preclnical and clinical studies
In: Conradie L, Garrett De Villiers J, Schaa VRW, eds. CYC2019. 22nd international conference on cyclotrons and their applications. Vol. 22. International conference on cyclotrons and their applications. Geneva: JACoW Publishing; 2020:132-135. https://doi.org/10.18429/JACoW-Cyclotrons2019-TUA03
DORA PSI

2019

Alcayne V, Kimura A, Mendoza E, Cano-Ott D, Aberle O, Amaducci S, et al.
Measurement of the ²⁴⁴Cm and ²⁴⁶Cm neutron-induced cross sections at the n_TOF facility
In: García-Ramos J-E, Andrés MV, Pérez-Bernal F, Valera JA, Moro AM, eds. Basic concepts in nuclear physics: theory, experiments and applications. 2018 La Rábida international scientific meeting on nuclear physics. Vol. 225. Springer proceedings in physics. Cham: Springer; 2019:117-122. https://doi.org/10.1007/978-3-030-22204-8_4
DORA PSI
Alcayne V, Kimura A, Mendoza E, Cano-Ott D, Martínez T, Aberle O, et al.
Measurement of the ²⁴⁴Cm and ²⁴⁶Cm neutron-induced capture cross sections at the n_TOF facility
In: Serot O, Chebboubi A, eds. WONDER-2018 - 5th international workshop on nuclear data evaluation for reactor applications. Vol. 211. EPJ web of conferences. sine loco: EDP Sciences; 2019:03008 (8 pp.). https://doi.org/10.1051/epjconf/201921103008
DORA PSI
Babiano-Suarez V, Caballero L, Domingo-Pardo C, Ladarescu I, Aberle O, Alcayne V, et al.
Characterization and first test of an i-TED prototype at CERN n_TOF
In: García-Ramos J-E, Andrés MV, Pérez-Bernal F, Valera JA, Moro AM, eds. Basic concepts in nuclear physics: theory, experiments and applications. 2018 La Rábida international scientific meeting on nuclear physics. Vol. 225. Springer proceedings in physics. Cham: Springer; 2019:169-173. https://doi.org/10.1007/978-3-030-22204-8_18
DORA PSI
Boss SD, Müller C, Siwowska K, Schmid RM, Groehn V, Schibli R, et al.
Diastereomerically pure 6R- and 6S-3'-aza-2'-¹⁸F-fluoro-5-methyltetrahydrofolates show unprecedentedly high uptake in folate receptor-positive KB tumors
Journal of Nuclear Medicine. 2019; 60(1): 135-141. https://doi.org/10.2967/jnumed.118.213314
DORA PSI
Brandl F, Merten H, Zimmermann M, Béhé M, Zangemeister-Wittke U, Plückthun A
Influence of size and charge of unstructured polypeptides on pharmacokinetics and biodistribution of targeted fusion proteins
Journal of Controlled Release. 2019; 307: 379-392. https://doi.org/10.1016/j.jconrel.2019.06.030
DORA PSI
Buitinga M, Jansen T, van der Kroon I, Woliner-van der Weg W, Boss M, Janssen M, et al.
Succinylated gelatin improves the theranostic potential of radiolabeled exendin-4 in insulinoma patients
Journal of Nuclear Medicine. 2019; 60(6): 812-816. https://doi.org/10.2967/jnumed.118.219980
DORA PSI
Carzaniga TS, van der Meulen NP, Hasler R, Kottler C, Peier P, Türler A, et al.
Measurement of the ⁴³Sc production cross-section with a deuteron beam
Applied Radiation and Isotopes. 2019; 145: 205-208. https://doi.org/10.1016/j.apradiso.2018.12.031
DORA PSI
Cicone F, Gnesin S, Denoël T, Stora T, van der Meulen NP, Müller C, et al.
Internal radiation dosimetry of a ¹⁵²Tb-labeled antibody in tumor-bearing mice
EJNMMI Research. 2019; 9: 53 (10 pp.). https://doi.org/10.1186/s13550-019-0524-7
DORA PSI
Gracheva N, Müller C, Talip Z, Heinitz S, Köster U, Zeevaart JR, et al.
Production and characterization of no-carrier-added ¹⁶¹Tb as an alternative to the clinically-applied ¹⁷⁷Lu for radionuclide therapy
EJNMMI Radiopharmacy and Chemistry. 2019; 4: 12 (16 pp.). https://doi.org/10.1186/s41181-019-0063-6
DORA PSI
Grzmil M, Meisel A, Behé M, Schibli R
An overview of targeted radiotherapy
In: Lewis JS, Windhorst AD, Zeglis BM, eds. Radiopharmaceutical chemistry. Cham: Springer; 2019:85-100. https://doi.org/10.1007/978-3-319-98947-1_5
DORA PSI
Grünberg J, Terraneo N
L1CAM. Ein vielversprechendes Zellmembranprotein für therapeutische Interventionen
Lead. Opin. Hämatol. Onkolog. 2019:6-8.
DORA PSI
He Y, Mu L, Ametamey SM, Schibli R
Recent progress in allosteric modulators for GluN2A subunit and development of GluN2A-selective nuclear imaging probes
Journal of Labelled Compounds and Radiopharmaceuticals. 2019; 62(8): 552-560. https://doi.org/10.1002/jlcr.3744
DORA PSI
Iacovacci V, Blanc A, Huang H, Ricotti L, Schibli R, Menciassi A, et al.
High‐resolution SPECT imaging of stimuli‐responsive soft microrobots
Small. 2019; 15(34): 1900709 (7 pp.). https://doi.org/10.1002/smll.201900709
DORA PSI
Jansen TJP, van Lith SAM, Boss M, Brom M, Joosten L, Béhé M, et al.
Exendin-4 analogs in insulinoma theranostics
Journal of Labelled Compounds and Radiopharmaceuticals. 2019; 62(10): 656-672. https://doi.org/10.1002/jlcr.3750
DORA PSI
Kaeppeli SAM, Schibli R, Mindt TL, Behe M
Comparison of desferrioxamine and NODAGA for the gallium-68 labeling of exendin-4
EJNMMI Radiopharmacy and Chemistry. 2019; 4(1): 9 (11 pp.). https://doi.org/10.1186/s41181-019-0060-9
DORA PSI
Kaeppeli SAM, Jodal A, Gotthardt M, Schibli R, Behe M
Exendin-4 derivatives with an albumin-binding moiety show decreased renal retention and improved GLP-1 receptor targeting
Molecular Pharmaceutics. 2019; 16(9): 3760-3769. https://doi.org/10.1021/acs.molpharmaceut.9b00271
DORA PSI
Kranzbühler B, Salemi S, Umbricht CA, Deberle LM, Müller C, Burger IA, et al.
Concentration‐dependent effects of dutasteride on prostate‐specific membrane antigen (PSMA) expression and uptake of ¹⁷⁷Lu‐PSMA‐617 in LNCaP cells
Prostate. 2019; 79(12): 1477-1483. https://doi.org/10.1002/pros.23868
DORA PSI
Müller C, De Prado Leal M, Dominietto MD, Umbricht CA, Safai S, Perrin RL, et al.
Combination of proton therapy and radionuclide therapy in mice: preclinical pilot sudy at the Paul Scherrer Institute
Pharmaceutics. 2019; 11(9): 450 (13 pp.). https://doi.org/10.3390/pharmaceutics11090450
DORA PSI
Müller C, Singh A, Umbricht CA, Kulkarni HR, Johnston K, Benešová M, et al.
Preclinical investigations and first-in-human application of ¹⁵²Tb-PSMA-617 for PET/CT imaging of prostate cancer
EJNMMI Research. 2019; 9(1): 68 (10 pp.). https://doi.org/10.1186/s13550-019-0538-1
DORA PSI
Müller C, Umbricht CA, Gracheva N, Tschan VJ, Pellegrini G, Bernhardt P, et al.
Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer
European Journal of Nuclear Medicine and Molecular Imaging. 2019; 46(9): 1919-1930. https://doi.org/10.1007/s00259-019-04345-0
DORA PSI
Pretze M, van der Meulen N P, Wängler C, Schibli R, Wängler B
Targeted ⁶⁴Cu-labeled gold nanoparticles for dual imaging with positron emission tomography and optical imaging
Journal of Labelled Compounds and Radiopharmaceuticals. 2019; 62(8): 471-482. https://doi.org/10.1002/jlcr.3736
DORA PSI
Radford LL, Fernandez S, Beacham R, Sayed RE, Farkas R, Benešová M, et al.
New ⁵⁵Co-labeled albumin-binding folate derivatives as potential PET agents for folate receptor imaging
Pharmaceuticals. 2019; 12(4): 166 (12 pp.). https://doi.org/10.3390/ph12040166
DORA PSI
Ritler A, Shoshan MS, Deupi X, Wilhelm P, Schibli R, Wennemers H, et al.
Elucidating the structure−activity relationship of the pentaglutamic acid sequence of minigastrin with cholecystokinin receptor subtype 2
Bioconjugate Chemistry. 2019; 30(3): 657-666. https://doi.org/10.1021/acs.bioconjchem.8b00849
DORA PSI
Ritter S, Grundler PV, Rowthu S
Assessment of the SCC mitigation capabilities of the NobleChem^TM technology in simulated BWR environment
Presented at: ICG-EAC Annual Meeting 2019; May 12-17, 2019; Tainan, Taiwan.
DORA PSI
Rowthu S, Yeh Y-W, Grundler PV, Holmes R, Ritter S
Assessment of the Pt nanoparticle distribution on oxidized stainless steel surfaces by electrochemical techniques
Presented at: EUROCORR 2019; September 9-13, 2019; Seville, Spain.
DORA PSI
Rupp NJ, Umbricht CA, Pizzuto DA, Lenggenhager D, Töpfer A, Müller J, et al.
First clinico-pathological evidence of a non PSMA-related uptake mechanism for ⁶⁸Ga-PSMA-11 in salivary glands
Journal of Nuclear Medicine. 2019; 60(9): 1270-1276. https://doi.org/10.2967/jnumed.118.222307
DORA PSI
Sauter AW, Mansi R, Hassiepen U, Muller L, Panigada T, Wiehr S, et al.
Targeting of the cholecystokinin-2 receptor with the minigastrin analog ¹⁷⁷Lu-DOTA-PP-F11N: does the use of protease inhibitors further improve in vivo distribution?
Journal of Nuclear Medicine. 2019; 60(3): 393-399. https://doi.org/10.2967/jnumed.118.207845
DORA PSI
Schniering J, Benešová M, Brunner M, Haller S, Cohrs S, Frauenfelder T, et al.
¹⁸F-AzaFol for detection of folate receptor-β positive macrophages in experimental interstitial lung disease - a proof-of-concept study
Frontiers in Immunology. 2019; 10: 2724 (15 pp.). https://doi.org/10.3389/fimmu.2019.02724
DORA PSI
Schniering J, Benešová M, Brunner M, Haller S, Cohrs S, Frauenfelder T, et al.
Visualisation of interstitial lung disease by molecular imaging of integrin αvβ3 and somatostatin receptor 2
Annals of the Rheumatic Diseases. 2019; 78(2): 218-227. https://doi.org/10.1136/annrheumdis-2018-214322
DORA PSI
Siwowska K, Guzik P, Domnanich KA, Monné Rodríguez JM, Bernhardt P, Ponsard B, et al.
Therapeutic potential of ⁴⁷Sc in comparison to ¹⁷⁷Lu and ⁹⁰Y: preclinical investigations
Pharmaceutics. 2019; 11(8): 424 (13 pp.). https://doi.org/10.3390/pharmaceutics11080424
DORA PSI
Umbricht CA, Köster U, Bernhardt P, Gracheva N, Johnston K, Schibli R, et al.
Alpha-PET for prostate cancer: preclinical investigation using ¹⁴⁹Tb-PSMA-617
Scientific Reports. 2019; 9: 17800 (10 pp.). https://doi.org/10.1038/s41598-019-54150-w
DORA PSI
Zhang J, Singh A, Kulkarni HR, Schuchardt C, Müller D, Wester H-J, et al.
From bench to bedside—the Bad Berka experience with first-in-human studies
Seminars in Nuclear Medicine. 2019; 49(5): 422-437. https://doi.org/10.1053/j.semnuclmed.2019.06.002
DORA PSI
van der Meulen NP, Hasler R, Blanc A, Farkas R, Benešová M, Talip Z, et al.
Implementation of a new separation method to produce qualitatively improved ⁶⁴Cu
Journal of Labelled Compounds and Radiopharmaceuticals. 2019; 62(8): 460-470. https://doi.org/10.1002/jlcr.3730
DORA PSI

2018

Visualisation of interstitial lung disease by molecular imaging of integrin αvβ3 and somatostatin receptor 2 Schniering J, Benešová M, Brunner M, Haller S, Cohrs S, Frauenfelder T, Vrugt B, Feghali-Bostwick CA, Schibli R, Distler O, Mueller C, Maurer B
ANNALS OF THE RHEUMATIC DISEASES , (2018).
DOI: annrheumdis-2018-214322
Design and Preclinical Evaluation of an Albumin-Binding PSMA Ligand for 64Cu-Based PET Imaging Umbricht CA, Benešová M, Hasler R, Schibli R, van der Meulen NP, Müller C
MOLECULAR PHARMACEUTICS , (2018).
DOI: acs.molpharmaceut.8b00712
Metabotropic glutamate receptor subtype 5 is altered in LPS-induced murine neuroinflammation model and in the brains of AD and ALS patients Müller Herde A, Schibli R, Weber M, Ametamey SM
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , (2018).
DOI: s00259-018-4179-9
In Vivo Labeling of Plasma Proteins for Imaging of Enhanced Vascular Permeability in the Lungs Schniering J, Borgna F, Siwowska K, Benešová M, Cohrs S, Hasler R, van der Meulen NP, Maurer B, Schibli R, Müller C
MOLECULAR PHARMACEUTICS 15, 4995 (2018).
DOI: acs.molpharmaceut.8b00606
Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma Lindenblatt D, Terraneo N, Pellegrini G, Cohrs S, Spycher PR, Vukovic D, Béhé M, Schibli R, Grünberg J
BMC CANCER 18, 922 (2018).
DOI: s12885-018-4836-1
Ketamine and Ceftriaxone-Induced Alterations in Glutamate Levels Do Not Impact the Specific Binding of Metabotropic Glutamate Receptor Subtype 5 Radioligand [18F]PSS232 in the Rat Brain Müller Herde A, Boss SD, He Y, Schibli R, Mu L, Ametamey SM
PHARMACEUTICASL (BASEL) E83, (2018).
DOI: ph11030083
Evaluation of 99mTc-rhAnnexin V-128 SPECT/CT as a diagnostic tool for early stages of interstitial lung disease associated with systemic sclerosis Schniering J, Guo L, Brunner M, Schibli R, Ye S, Distler O, Béhé M, Maurer B
ATHRITIS RESEARCH AND THERAPY 20, 183 (2018).
DOI: s13075-018-1681-1
Identification and Preclinical Evaluation of a Radiofluorinated Benzazepine Derivative for Imaging the GluN2B Subunit of the Ionotropic NMDA Receptor Haider A, Iten I, Ahmed H, Müller Herder A, Gruber S, Krämer SD, Keller C, Schibli R, Wünsch B, Mu L, Ametamey SM
JOURNAL OF NUCLEAR MEDICINE , (2018).
DOI: jnumed.118.212134
Physiologically Based Pharmacokinetic Modelling with Dynamic PET Data to Study the In Vivo Effects of Transporter Inhibition on Hepatobiliary Clearance in Mice Taddio MF, Mu L, Keller C, Schibli R, Krämer SD
CONTRAST MEDIA AND MOLECULAR IMAGING 5849047, (2018).
DOI: 5849047
Unexpected reactivity of cyclic perfluorinated iodanes with electrophiles Gruber S, Ametamey SM , Schibli R
CHEMICAL COMMUNICATIONS 54, 8999 (2018).
DOI: c8cc04558e
Diastereomerically Pure 6R- and 6S-3'-aza-2'-18F-Fluoro-5-Methyltetrahydrofolates Show Unprecedented High Uptake in Folate Receptor-positive KB Tumors Boss SD, Müller C, Siwowska K, Schmid RM, Groehn V, Schibli R, Ametamey SM
JOURNAL OF NUCLEAR MEDICINE , (2018).
DOI: jnumed.118.213314
Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells Kranzbühler B, Salemi S, Umbricht CA, Müller C, Burger IA, Sulser T, Eberli D
PROSTATE 78, 758 (2018).
DOI: pros.23522
Combining Albumin-Binding Properties and Interaction with Pemetrexed to Improve the Tissue Distribution of Radiofolates Müller C, Guzik P, Siwowska K, Cohrs S, Schmid RM, Schibli R
MOLECULES 23, E1465 (2018).
DOI: molecules23061465
Scandium and terbium radionuclides for radiotheranostics: current state of development towards clinical application Müller C, Domnanich KA, Umbricht CA, van der Meulen NP
BRITISH JOURNAL OF RADIOLOGY , (2018).
DOI: bjr.20180074
Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy Umbricht CA, Benešová M, Schibli R, Müller C
MOLECULAR PHARMACEUTICALS , (2018).
DOI: acs.molpharmaceut.8b00152
Injected Human Muscle Precursor Cells Overexpressing PGC-1α Enhance Functional Muscle Regeneration after Trauma Haralampieva D, Salemi S, Betzel T, Dinulovic I, Krämer SD, Schibli R, Sulser T, Handschin C, Ametamey SM, Eberli D
STEM CELL INTERNATIONAL 2018, 465850 (2018).
DOI: 4658503
Radiosynthesis and evaluation of an 18F-labeled silicon containing exendin-4 peptide as a PET probe for imaging insulinoma Dialer LO, Jodal A, Schibli R, Ametamey SM, Béhé M
EJNMMI RADIOPHARMACY AND CHEMISTRY 3, 1 (2018).
DOI: s41181-017-0036-6
Improved Syntheses of the Mglu₅ Antagonists MMPEP and MTEP Using Sonogashira Cross-Coupling Mu B, Mu L, Schibli R, Ametamey SM, Milicevic Sephton S
PHARMACEUTICALS (BASEL) 11, E24 (2018).
DOI: ph11010024
Evaluation of 4-oxo-quinoline-based CB2 PET radioligands in R6/2 chorea huntington mouse model and human ALS spinal cord tissue Haider A, Spinelli F, Herde AM, Mu B, Keller C, Margelisch M, Weber M, Schibli R, Mu L, Ametamey SM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 145, 746 (2018).
DOI: j.ejmech.2017.12.097
Evaluation of 11C-Me-NB1 as a Potential PET Radioligand for Measuring GluN2B-Containing NMDA Receptors, Drug Occupancy, and Receptor Cross Talk Krämer SD, Betzel T, Mu L, Haider A, Herde AM, Boninsegni AK, Keller C, Szermerski M, Schibli R, Wünsch B, Ametamey SM
JOURNAL OF NUCLEAR MEDICINE 59, 698 (2018).
DOI: jnumed.117.200451
A first-in-man PET study of [18F]PSS232, a fluorinated ABP688 derivative for imaging metabotropic glutamate receptor subtype 5 Warnock G, Sommerauer M, Mu L, Pla Gonzalez G, Geistlich S, Treyer V, Schibli R, Buck A, Krämer SD, Ametamey SM
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 45, 1041 (2018).
DOI: s00259-017-3879-x
Imaging of Folate Receptor Expressing Macrophages in the Rat Groove Model of Osteoarthritis: Using a New DOTA-Folate Conjugate de Visser HM, Korthagen NM, Müller C, Ramakers RM, Krijger GC, Lafeber FPJG, Beekman FJ, Mastbergen SC, Weinans H
CARTILAGE 9, 183 (2018).
DOI: 1947603517738073
Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile Benešová M, Umbricht CA, Schibli R, Müller C
MOLECULAR PHARMACEUTICS 15, 934 (2018).
DOI: acs.molpharmaceut.7b00877
Reduced 18F-Folate Conjugates as a New Class of PET Tracers for Folate Receptor Imaging Boss SD, Müller C, Siwowska K, Büchel JI, Schmid RM, Groehn V, Schibli R, Ametamey SM
BIOCONJUGATE CHEMISTRY 29, 1119 (2018).
DOI: acs.bioconjchem.7b00775

2017

Metabotropic glutamate receptor 5 binding in male patients with alcohol use disorder Akkus F, Mihov Y, Treyer V, Ametamey SM, Johayem A, Senn S, Rösner S, Buck A, Hasler G
TRANSLATIONAL PSYCHIATRY 8, 17 (2017).
DOI: s41398-017-0066-6
Imaging the glutamate receptor subtypes-Much achieved, and still much to do Gruber S, Ametamey SM
DRUG DISCOVERY TODAY: TECHNOLOGIES 25, 27 (2017).
DOI: j.ddtec.2017.10.006
Radioligands for positron emission tomography imaging of cannabinoid type 2 receptor Spinelli F, Mu L, Ametamey SM
JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS , (2017).
DOI: jlcr.3579
Cerebral mGluR5 availability contributes to elevated sleep need and behavioral adjustment after sleep deprivation Holst SC, Sousek A, Hefti K, Saberi-Moghadam S, Buck A, Ametamey SM, Scheidegger M, Franken P, Henning A, Seifritz E, Tafti M, Landolt HP
eLIFE , e28751 (2017).
DOI: eLife.28751
Novel peptide probes to assess the tensional state of fibronectin fibers in cancer Arnoldini S, Moscaroli A, Chabria M, Hilbert M, Hertig S, Schibli R, Béhé M, Vogel V
NATURE COMMUNICATIONS 8, 1793 (2017).
DOI: s41467-017-01846-0
Towards Translational ImmunoPET/MR Imaging of Invasive Pulmonary Aspergillosis: The Humanised Monoclonal Antibody JF5 Detects Aspergillus Lung Infections In Vivo Davies G, Rolle AM, Maurer A, Spycher PR, Schillinger C, Solouk-Saran D, Hasenberg M, Weski J, Fonslet J, Dubois A, Boschetti F, Denat F, Gunzer M, Eichner M, Ryder LS, Jensen M, Schibli R, Pichler BJ, Wiehr S, Thornton CR
THERANOSTICS 7, 3398 (2017).
DOI: thno.20919
Synthesis, Radiolabeling, and Characterization of Plasma Protein-Binding Ligands: Potential Tools for Modulation of the Pharmacokinetic Properties of (Radio)Pharmaceuticals Müller C, Farkas R, Borgna F, Schmid RM, Benešová M, Schibli R
BIOCONJUGATE CHEMISTRY 28, 2372 (2017).
DOI: acs.bioconjchem.7b00378
Therapeutic Radiometals Beyond 177Lu and 90Y: Production and Application of Promising α-Particle, β--Particle, and Auger Electron Emitters Müller C, van der Meulen NP, Benešová M, Schibli R
JOURNAL OF NUCLEAR MEDICINE 58 (Suppl 2), 91S (2017).
DOI: jnumed.116.186825
Clinical evaluation of the radiolanthanide terbium-152: first-in-human PET/CT with 152Tb-DOTATOC Baum RP, Singh A, Benešová M, Vermeulen C, Gnesin S, Köster U, Johnston K, Müller D, Senftleben S, Kulkarni HR, Türler A, Schibli R, Prior JO, van der Meulen NP, Müller C
DALTON TRANSACTION 46, 14638 (2017).
DOI: c7dt01936j
Folate Receptor-Positive Gynecological Cancer Cells: In Vitro and In Vivo Characterization Siwowska K, Schmid RM, Cohrs S, Schibli R, Müller C
PHARMACEUTICALS (BASEL) 10, E72 (2017).
DOI: ph10030072
Dual, Site-Specific Modification of Antibodies by Using Solid-Phase Immobilized Microbial Transglutaminase Spycher PR, Amann CA, Wehrmüller JE, Hurwitz DR, Kreis O, Messmer D, Ritler A,3, Küchler A, Blanc A, Béhé M, Walde P, Schibli R
CHEMBIOCHEM 18, 1923 (2017).
DOI: cbic.201700188
A Short-Term Biological Indicator for Long-Term Kidney Damage after Radionuclide Therapy in Mice Pellegrini G, Siwowska K, Haller S, Antoine DJ, Schibli R, Kipar A, Müller C
PHARMACEUTICALS (BASEL) 10, E57 (2017).
DOI: ph10020057
First-in-Human PET/CT Imaging of Metastatic Neuroendocrine Neoplasms with Cyclotron-Produced 44Sc-DOTATOC: A Proof-of-Concept Study Singh A,van der Meulen NP, Müller C, Klette I, Kulkarni HR, Türler A, Schibli R, Baum RP
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS 32, 124 (2017).
DOI: cbr.2016.2173
Radiolabeled 111In-FGF-2 Is Suitable for In Vitro/Ex Vivo Evaluations and In Vivo Imaging Moscaroli A, Jones G, Lühmann T, Meinel L, Wälti S, Blanc A, Fischer E, Hilbert M, Schibli R, Béhé M
MOLECULAR PHARMACEUTICS 14, 639 (2017).
DOI: acs.molpharmaceut.6b0091
Automated cGMP-compliant radiosynthesis of [18 F]-(E)-PSS232 for brain PET imaging of metabotropic glutamate receptor subtype 5 Park JY, Son J, Yun M, Ametamey SM, Chun JH
JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS , (2017).
DOI: jlcr.3566
Human Muscle Precursor Cells Overexpressing PGC-1α Enhance Early Skeletal Muscle Tissue Formation Haralampieva D, Salemi S, Dinulovic I, Sulser T, Ametamey SM, Handschin C, Eberli D
CELL TRANSPLANTATION 26, 1103 (2017).
DOI: 096368917X694868
Kinetics of lipid bilayer permeation of a series of ionisable drugs and their correlation with human transporter-independent intestinal permeability Hermann KF, Neuhaus CS, Micallef V, Wagner B, Hatibovic M, Aschmann HE, Paech F, Alvarez-Sanchez R, Krämer SD, Belli S
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES 104, 150 (2017).
DOI: j.ejps.2017.03.040
GABAA receptor subtypes in the mouse brain: Regional mapping and diazepam receptor occupancy by in vivo [18F]flumazenil PET Müller Herde A, Benke D, Ralvenius WT, Mu L, Schibli R, Zeilhofer HU, Krämer SD
NEUROIMAGE 15, 279 (2017).
DOI: j.neuroimage.2017.02.022
Cannabinoid receptor type 2 (CB2) as one of the candidate genes in human carotid plaque imaging: Evaluation of the novel radiotracer [11C]RS-016 targeting CB2 in atherosclerosis Meletta R, Slavik R, Mu L, Rancic Z, Borel N, Schibli R, Ametamey SM, Krämer SD, Müller Herde A
NUCLEAR MEDICINE AND BIOLOGY 47, 31 (2017).
DOI: j.nucmedbio.2017.01.001
44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617-preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617 Umbricht CA, Benešová M, Schmid RM, Türler A, Schibli R, van der Meulen NP, Müller C
EJNMMI RESEARCH 7, 9 (2017).
DOI: s13550-017-0257-4
Metabotropic glutamate receptor 5 neuroimaging in schizophrenia Akkus F, Treyer V, Ametamey SM, Johayem A, Buck A, Hasler G
SCHIZOPHRENIA RESEARCH 183, 95 (2017).
DOI: j.schres.2016.11.008
Preclinical Comparison of Albumin-Binding Radiofolates: Impact of Linker Entities on the in Vitro and in Vivo Properties Siwowska K, Haller S, Bortoli F, Benešová M, Groehn V, Bernhardt P, Schibli R, Müller C
MOLECULAR PHARMACEUTICS 14, 523 (2017).
DOI: acs.molpharmaceut.6b01010
Methoxinine - an alternative stable amino acid substitute for oxidation-sensitive methionine in radiolabelled peptide conjugates Grob NM, Behe M, von Guggenberg E, Schibli R, Mindt TL
JOURNAL OF PEPTIDE SCIENCE 23, 38 (2017).
DOI: psc.2948
Targets and probes for non-invasive imaging of β-cells Jodal A, Schibli R, Béhé M
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 44, 712 (2017).
DOI: s00259-016-3592-1

2016

44Sc for labeling of DOTA- and NODAGA functionalized peptides: preclinical in vitro and in vivo investigations Domnanich KA, Müller C, Farkas R, Schmid RM, Ponsard B, Schibli S, Türler A, van der Meulen NP
EJNMMI RADIOPHARMACY AND CHEMISTRY 1, 5 (2016).
DOI: s41181-016-0013-5
Alpha-PET with terbium-149: evidence and perspectives for radiotheragnostics Müller C, Vermeulen C, Köster U, Johnston K, Türler A, Schibli R, van der Meulen NP
EJNMMI RADIOPHARMACY AND CHEMISTRY 1, 5 (2016).
DOI: s41181-016-0008-2
Preclinical in vivo application of (152)Tb-DOTANOC: a radiolanthanide for PET imaging Müller C, Vermeulen C, Johnston K, Köster U, Schmid R, Türler A, van der Meulen NP
EJNMMI RESEARCH 6, 35 (2016).
DOI: s13550-016-0189-4
Evaluation of the first 44Sc-labeled Affibody molecule for imaging of HER2-expressing tumors Honarvar H, Müller C, Cohrs S, Haller S, Westerlund K, Karlström AE, van der Meulen NP, Schibli R, Tolmachev V
NUCLEAR MEDICINE AND BIOLOGY 45, 15 (2016).
DOI: j.nucmedbio.2016.10.004
Production of (28)Mg by bombardment of (nat)Cl with 200MeV protons: Proof-of-concept study for a stacked LiCl target van der Meulen NP, Steyn GF, Vermeulen C, van Rooyen TJ
APPLIED RADIATION AND ISOTOPES 115, 125 (2016).
DOI: j.apradiso.2016.04.026
Enhanced sensitivity to drugs of abuse and palatable foods following maternal overnutrition Peleg-Raibstein D, Sarker G, Litwan K, Krämer SD, Ametamey SM, Schibli R, Wolfrum C
TRANSLATIONAL PSYCHIATRY 6, e911 (2016).
DOI: tp.2016.176
Synthesis and Pharmacological Evaluation of [11C]Granisetron and [18F]Fluoropalonosetron as PET Probes for 5-HT3 Receptor Imaging Mu L, Müller Herde A, Rüefli PM, Sladojevich F, Milicevic Sephton S, Krämer SD, Thompson AJ, Schibli R, Ametamey SM, Lochner M
ACS CHEMICAL NEUROSCIENCE 7, 1552 (2016).
DOI: acschemneuro.6b00192
Synthesis and Biological Evaluation of Thiophene-Based Cannabinoid Receptor Type 2 Radiotracers for PET Imaging Haider A, Müller Herde A, Slavik R, Weber M, Mugnaini C, Ligresti A, Schibli R, Mu L, Mensah Ametamey S
FRONTIERS IN NEUROSCIENCE 10, 350 (2016).
DOI: fnins.2016.00350
CD80 Is Upregulated in a Mouse Model with Shear Stress-Induced Atherosclerosis and Allows for Evaluating CD80-Targeting PET Tracers Meletta R, Steier L, Borel N, Mu L, Keller C, Chiotellis A, Russo E, Halin C, Ametamey SM, Schibli R, Krämer SD, Müller Herde A
MOLUCULAR IMAGING and BIOLOGY Epub ahead of print, (2016).
DOI: s11307-016-0987-0
Discovery of a Fluorinated 4-Oxo-Quinoline Derivative as a Potential PET Radiotracer for Imaging CB2 Receptor Slavik R, Müller Herde A, Haider A, Krämer SD, Weber M, Schibli R, Ametamey SM, Mu L
JOURNAL OF NEUROCHEMISTRY 138, 874 (2016).
DOI: jnc.13716
Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy Grzmil M, Seebacher J, Hess D, Behe M, Schibli R, Moncayo G, Frank S, Hemmings BA
CELLULAR SIGNALLING 28, 1412 (2016).
DOI: j.cellsig.2016.06.005
Non-invasive Imaging and Tracking of Engineered Human Muscle Precursor Cells for Skeletal Muscle Tissue Engineering Using Positron Emission Tomography Haralampieva D, Betzel T, Dinulovic I, Salemi S, Stoelting M, Krämer S, Schibli R, Sulser T, Handschin C, Eberli D, Ametamey SM
JOURNAL OF NUCLEAR MEDICINE Epub ahead of print, (2016).
DOI:
Synthesis, Radiolabeling, and Biological Evaluation of 5-Hydroxy-2-[(18)F]fluoroalkyl-tryptophan Analogues as Potential PET Radiotracers for Tumor Imaging Chiotellis A, Müller Herde A, Rössler SL, Brekalo A1, Gedeonova E, Mu L, Keller C, Schibli R, Krämer SD, Ametamey SM
JOURNAL OF MEDICINAL CHEMISTRY 59, 5324 (2016).
DOI: acs.jmedchem.6b00057
(64)Cu- and (68)Ga-Based PET Imaging of Folate Receptor-Positive Tumors: Development and Evaluation of an Albumin-Binding NODAGA-Folate Farkas R, Siwowska K, Ametamey SM, Schibli R, van der Meulen NP, Müller C
MOLECULAR PHARMACEUTICS 13, 1979 (2016).
DOI: acs.molpharmaceut.6b00143
Novel chemoselective (18)F-radiolabeling of thiol-containing biomolecules under mild aqueous conditions Chiotellis A, Sladojevich F, Mu L, Müller Herde A, Valverde IE, Tolmachev V, Schibli R, Ametamey SM, Mindt TL
CHEMICAL COMMUNICATION 52, 6083 (2016).
DOI: c6cc01982j
Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of (161)Tb-folate and (177)Lu-folate Haller S, Pellegrini G, Vermeulen C, van der Meulen NP, Köster U, Bernhardt P, Schibli R, Müller C
EJNMMI RESEARCH 1, 13 (2016).
DOI: s13550-016-0171-1
ImmunoPET/MR imaging allows specific detection of Aspergillus fumigatus lung infection in vivo Rolle AM, Hasenberg M, Thornton CR, Solouk-Saran D, Männ L, Weski J, Maurer A, Fischer E, Spycher PR, Schibli R, Boschetti F, Stegemann-Koniszewski S, Bruder D, Severin GW, Autenrieth SE, Krappmann S, Davies G, Pichler BJ, Gunzer M, Wiehr S
PNAS 113, E1026 (2016).
DOI: pnas.1518836113
Imaging quality of (44)Sc in comparison with five other PET radionuclides using Derenzo phantoms and preclinical PET Bunka M, Müller C, Vermeulen C, Haller S, Türler A, Schibli R, van der Meulen NP
APPLIED RADIATION AND ISOTOPES 110, 129 (2016).
DOI: j.apradiso.2016.01.006
Preclinical imaging of the co-stimulatory molecules CD80 and CD86 with indium-111-labeled belatacept in atherosclerosis Meletta R, Müller Herde A, Dennler P, Fischer E, Schibli R, Krämer SD
EJNMMI RESEARCH 6, 1 (2016).
DOI: s13550-015-0157-4
Comparative Studies of Three Pairs of α- and γ-Conjugated Folic Acid Derivatives Labeled with Fluorine-18 Boss SD, Betzel T, Müller C, Fischer CR, Haller S, Reber J, Groehn V, Schibli R, Ametamey SM
BIOCONJUGATE CHEMISTRY 27, 74 (2016).
DOI: acs.bioconjchem.5b00644

2015

Ex vivo differential phase contrast and magnetic resonance imaging for characterization of human carotid atherosclerotic plaque Meletta R, Borel N, Stolzmann P, Astolfo A, Klohs J, Stampanoni M, Rudin M, Schibli R, Krämer SD, Müller Herde A
THE INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING 31, 1425 (2015).
DOI: s10554-015-0706-y
Folate receptor-targeted radionuclide therapy: preclinical investigation of anti-tumor effects and potential radionephropathy Haller S, Reber J, Brandt S, Bernhardt P, Groehn V, Schibli R, Müller C
NUCLEAR MEDICINE AND BIOLOGY 42, 770 (2015).
DOI: j.nucmedbio.2015.06.006
Cyclotron production of (44)Sc: From bench to bedside van der Meulen NP, Bunka M, Domnanich KA, Müller C, Haller S, Vermeulen C, Türler A, Schibli R
NUCLEAR MEDICINE AND BIOLOGY 42, 745 (2015).
DOI: j.nucmedbio.2015.05.00
Longitudinal in vivo evaluation of bone regeneration by combined measurement of multi-pinhole SPECT and micro-CT for tissue engineering Lienemann PS, Metzger S, Kiveliö AS, Blanc A, Papageorgiou P, Astolfo A, Pinzer BR, Cinelli P, Weber FE, Schibli R, Béhé M, Ehrbar M
SCIENTIFIC REPORTS 5, 10238 (2015).
DOI: srep10238 Erratum DOI: srep12391
Discovery of a high affinity and selective pyridine analog as a potential positron emission tomography imaging agent for cannabinoid type 2 receptor Slavik R, Grether U, Müller Herde A, Gobbi L, Fingerle J, Ullmer C, Krämer SD, Schibli R, Mu L, Ametamey SM
JOURNAL OF MEDICINAL CHEMISTRY 58, 4266 (2015).
DOI: acs.jmedchem.5b00283
Evaluation of a Novel Tc-99m Labelled Vitamin B12 Derivative for Targeting Escherichia coli and Staphylococcus aureus In Vitro and in an Experimental Foreign-Body Infection Model Baldoni D, Waibel R, Bläuenstein P, Galli F, Iodice V, Signore A, Schibli R, Trampuz A
MOLECULAR IMAGING AND BIOLOGY 10, e0123443 (2015).
DOI: s11307-015-0832-x
Evaluation of ¹¹¹in-labelled exendin-4 derivatives containing different meprin β-specific cleavable linkers Jodal A, Pape F, Becker-Pauly C, Maas O, Schibli R, Béhé M
PLOS ONE 10, e0123443 (2015).
DOI: journal.pone.0123443
Regional cerebral blood flow estimated by early PiB uptake is reduced in mild cognitive impairment and associated with age in an amyloid-dependent manner Gietl AF, Warnock G, Riese F, Kälin AM, Saake A, Gruber E, Leh SE, Unschuld PG, Kuhn FP, Burger C, Mu L, Seifert B, Nitsch RM, Schibli R, Ametamey SM, Buck A, Hock C
NEUROBIOLOGY OF AGING 36, 1619 (2015).
DOI: j.neurobiolaging.2014.12.036
Microbial transglutaminase and c-myc-tag: a strong couple for the functionalization of antibody-like protein scaffolds from discovery platforms Dennler P, Bailey LK, Spycher PR, Schibli R, Fischer E
CHEMBIOCHEM 16, 861 (2015).
DOI: cbic.201500009
Dosimetry and first clinical evaluation of the new 18F-radiolabeled bombesin analogue BAY 864367 in patients with prostate cancer Sah BR, Burger IA, Schibli R, Friebe M, Dinkelborg L, Graham K, Borkowski S, Bacher-Stier C, Valencia R, Srinivasan A, Hany TF, Mu L, Wild PJ, Schaefer NG
JOURNAL OF NUCLEAR MEDICINE 56, 372 (2015).
DOI: jnumed.114.147116
Synthesis and pharmacological evaluation of ¹¹C-labeled piperazine derivative as a PET probe for sigma-2 receptor imaging Selivanova SV, Toscano A, Abate C, Berardi F, Müller A, Krämer SD, Schibli R, Ametamey SM
NUCLEAR MEDICINE AND BIOLOGY 42, 399 (2015).
DOI: j.nucmedbio.2014.12.018
Evaluation of the radiolabeled boronic acid-based FAP inhibitor MIP-1232 for atherosclerotic plaque imaging Meletta R, Müller Herde A, Chiotellis A, Isa M, Rancic Z, Borel N, Ametamey SM, Krämer SD, Schibli R
MOLUCULES 20, 2081 (2015).
DOI: molecules20022081
Investigation of the chick embryo as a potential alternative to the mouse for evaluation of radiopharmaceuticals Haller S, Ametamey SM, Schibli R, Müller C
NUCLEAR MEDICINE AND BIOLOGY 42, 226 (2015).
DOI: j.nucmedbio.2014.10.010
Quantitative positron emission tomography of mGluR5 in rat brain with [(18) F]PSS232 at minimal invasiveness and reduced model complexity Müller Herde A, Keller C, Milicevic Sephton S, Mu L, Schibli R, Ametamey SM, Krämer SD
JOURNAL OF NEUROCHEMISTRY 133, 330 (2015).
DOI: jnc.13001
Site-Specific Conjugation of Monomethyl Auristatin E to Anti-CD30 Antibodies Improves Their Pharmacokinetics and Therapeutic Index in Rodent Models Lhospice F, Delphine B, Belmant C, Patrick D, Aristeidis C, Fischer E, Laurent G, Bonnafous C, Viaud N, Represa A, Boëdec A, Rispaud Blanc H, Sapet M, Delcambre C, Ingoure S, Savard Chambard S, Schneider N, Paturel C, Schibli R, Romagne F
MOLECULAR PHARMACEUTICS 12, 1863 (2015).
DOI: mp500666j
Association of Long-Term Nicotine Abstinence with Normal Metabotropic Glutamate Receptor-5 Binding Akkus F, Treyer V, Johayem A, Ametamey SM, Mancilla BG, Sovago J, Buck A, Hasler G
BIOLOGYCAL PSYCHATRY , (2015).
DOI: 10.1016/j.biopsych.2015.02.027
Synthesis, radiolabeling and evaluation of novel 4-oxo-quinoline derivatives as PET tracers for imaging cannabinoid type 2 receptor Slavik R, Herde AM1, Bieri D, Weber M, Schibli R, Krämer SD, Ametamey SM, Mu L
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 92, 554 (2015).
DOI: j.ejmech.2015.01.028
Folate Receptor-Targeted Multimodality Imaging of Ovarian Cancer in a Novel Syngeneic Mouse Model Ocak M, Gillman AG, Bresee J, Zhang L, Vlad AM, Müller C, Schibli R, Edwards WB, Anderson CJ, Gach HM
MOLECULAR PHARMACEUTICS 12, 542 (2015).
DOI: mp500628g
Self-assembled gold coating enhances X-ray imaging of alginate microcapsules Qie F, Astolfo A, Wickramaratna M, Behe M, Evans MD, Hughes TC, Hao X, Tan T
NANOSCALE 7, 2480 (2015).
DOI: c4nr06692h
Excitation functions of natZr + p nuclear processes up to 70 MeV: New measurements and compilation Szelecsényi F, Steyn GF, Kovács Z, Vermeulen C, Nagatsu K, Zhang MR, Suzuki K
NUCLEAR INSTRUMENTS AND METHODS IN PHYSICS RESEARCH B 343, 173 (2015).
DOI: j.nimb.2014.11.081
Preclinical evaluation and test-retest studies of [(18)F]PSS232, a novel radioligand for targeting metabotropic glutamate receptor 5 (mGlu5) Sephton SM, Herde AM, Mu L, Keller C, Rüdisühli S, Auberson Y, Schibli R, Krämer SD, Ametamey SM
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 42, 128 (2015).
DOI: s00259-014-2883-7

Contact

Prof. Dr. Roger Schibli

Head of the Center for Radiopharmaceutical Sciences ETH-PSI-USZ

roger.schibli@psi.ch

+41 56 310 28 37

Sandha Keller

Assistentin der Laborleitung

sandha.keller@psi.ch

+41 56 310 44 05

Contact ETH
Prof. Dr. Roger Schibli
Swiss Federal Institute of Technology Zurich
Radiopharmaceutical Sciences
ETH Zurich